文献一覧: Tetsuya SUZUKI (著者)

10 0 0 0 OA COVID-19 can suddenly become severe: a case series from Tokyo, Japan

著者: Keiji Nakamura Satoshi Ide Sho Saito Noriko Kinoshita Satoshi Kutsuna Yuki Moriyama Tetsuya Suzuki Masayuki Ota Hidetoshi Nomoto Tetsuya Mizoue Masayuki Hojo Jin Takasaki Yusuke Asai Mari Terada Yutaro Akiyama Yusuke Miyazato Takato Nakamoto Yuji Wakimoto Mugen Ujiie Kei Yamamoto Masahiro Ishikane Shinichiro Morioka Kayoko Hayakawa Haruhito Sugiyama Norio Ohmagari
出版者: National Center for Global Health and Medicine
雑誌: Global Health & Medicine (ISSN:24349186)
巻号頁・発行日: vol.2, no.3, pp.174-177, 2020-06-30 (Released:2020-07-04)
参考文献数: 8
被引用文献数: 7

Since the initial report of coronavirus disease (COVID-19) from the City of Wuhan, China in December 2019, there have been multiple cases globally. Reported here are 11 cases of COVID-19 at this hospital; all of the patients in question presented with relative bradycardia. The severity of the disease was classified into four grades. Of the patients studied, 3 with mild COVID-19 and 3 with moderate COVID-19 improved spontaneously. Lopinavir/ritonavir was administered to 3 patients with severe COVID-19 and 2 with critical COVID-19. Both patients with critical COVID-19 required mechanical ventilation and extracorporeal membrane oxygenation. Both patients with critical COVID-19 had a higher fever that persisted for longer than patients with milder COVID-19. The respiratory status of patients with critical COVID-19 worsened rapidly 7 days after the onset of symptoms. Relative bradycardia may be useful in distinguishing between COVID-19 and bacterial community-acquired pneumonia. In patients who have had a fever for > 7 days, the condition might worsen suddenly.

2022-01-20 20:31:39
10 + 35 Twitter

6 0 0 0 OA A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan

著者: Rubuna Sato Masahiro Ishikane Noriko Kinoshita Tetsuya Suzuki Takato Nakamoto Kayoko Hayakawa Norifumi Bekki Hisao Hara Norio Ohmagari
出版者: National Center for Global Health and Medicine
雑誌: Global Health & Medicine (ISSN:24349186)
巻号頁・発行日: pp.2020.01044, (Released:2020-05-15)
参考文献数: 13
被引用文献数: 14

Hypercoagulation and anticoagulation treatment have become new challenges in coronavirus disease 2019 (COVID-19) patients during the COVID-19 pandemic. We herein suggest an algorithm for an anticoagulation treatment with unfractionated heparin in moderate to severe COVID-19 cases in Japan, and report a case of COVID-19 pneumonia with anticoagulation treatment. Although several promising drugs for COVID-19 are being tested in clinical trials, definitive treatments have not yet been established. In this report, we demaonstrate that anticoagulation treatment with unfractionated heparin has the possibility of becoming at least a supportive treatment for COVID-19 patients.

2020-06-23 12:31:58
6 + 1 Twitter

5 0 0 0 OA SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine

著者: Kayoko Hayakawa Satoshi Kutsuna Takeo Kawamata Yuko Sugiki Chiharu Nonaka Keiko Tanaka Michi Shoji Masaki Nagai Shunsuke Tezuka Kazuyuki Shinya Hiroki Saito Takahiro Harada Nin Moriya Motoyuki Tsuboi Masataro Norizuki Yasuo Sugiura Yasuyo Osanai Masaya Sugiyama Ayako Okuhama Kohei Kanda Yuji Wakimoto Mugen Ujiie Shinichiro Morioka Kei Yamamoto Noriko Kinoshita Masahiro Ishikane Sho Saito Yuki Moriyama Masayuki Ota Keiji Nakamura Takato Nakamoto Satoshi Ide Hidetoshi Nomoto Yutaro Akiyama Tetsuya Suzuki Yusuke Miyazato Yoshiaki Gu Nobuaki Matsunaga Shinya Tsuzuki Yumiko Fujitomo Yoshiki Kusama Hiroyuki Shichino Masao Kaneshige Junko Yamanaka Miki Saito Masayuki Hojo Masao Hashimoto Shinyu Izumi Jin Takasaki Manabu Suzuki Keita Sakamoto Yukio Hiroi Sakurako Emoto Makoto Tokuhara Toshiaki Kobayashi Koichiro Tomiyama Fumihiko Nakamura Norio Ohmagari Haruhito Sugiyama
出版者: National Center for Global Health and Medicine
雑誌: Global Health & Medicine (ISSN:24349186)
巻号頁・発行日: vol.2, no.2, pp.107-111, 2020-04-30 (Released:2020-05-10)
参考文献数: 11
被引用文献数: 25

Due to the significant spread of a new type of coronavirus (SARS-CoV-2) infection (COVID-19) in China, the Chinese government blockaded several cities in Hubei Province. Japanese citizens lost a means of transportation to return back to Japan. The National Center for Global Health and Medicine (NCGM) helped the operation of charter flights for evacuation of Japanese residents from Hubei Province, and this article outlines our experiences. A total of five charter flights were dispatched, and the majority of returnees (793/829 [95.7%]) were handled at NCGM. A large number of personnel from various departments participated in this operation; 107 physicians, 115 nurses, 110 clerical staff, and 45 laboratory technicians in total. Several medical translators were also involved. In this operation, we conducted airborne precautions in addition to contact precautions. Eye shields were also used. The doctors collecting the pharyngeal swab used a coverall to minimize the risk of body surface contamination from secretions and droplets. Enhanced hand hygiene using alcohol hand sanitizer was performed. Forty-eight persons were ultimately hospitalized after the triage at NCGM operation, which was more than the number of persons triaged at the airport (n = 34). Of those hospitalized after NCGM triage, 8.3% (4/48 patients) ultimately tested positive for SARS-CoV-2, significantly higher than the positive rate among subjects not triaged (4/48 [8.3%] vs. 9/745 [1.2%]: p = 0.0057). NCGM participated in a large-scale operation to evacuate Japanese nationals from the COVID-19 epidemic area. We were able to establish a scheme through this experience that can be used in the future.

2022-01-20 20:31:41
5 + 19 Twitter

3 0 0 0 OA A Case of COVID-19 Patient with False-negative for SARS-CoV-2 of Pharyngeal Swab, from a Chinese traveller Returning from Wuhan, Hubei Province, China, January 2020

著者: Masahiro Ishikane Yusuke Miyazato Satoshi Kustuna Tetsuya Suzuki Satoshi Ide Keiji Nakamura Shinichiro Morioka Harutaka Katano Tadaki Suzuki Norio Ohmagari
出版者: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
雑誌: Japanese Journal of Infectious Diseases (ISSN:13446304)
巻号頁・発行日: pp.JJID.2020.240, (Released:2020-05-29)
参考文献数: 14
被引用文献数: 1

We report a case of patient in Japan with Coronavirus disease 2019 (COVID-19) with false-negative of reverse transcription polymerase chain reaction for Severe Acute Respiratory Syndrome Coronavirus 2 of pharyngeal swab, from a Chinese traveller returning from Wuhan, Hubei Province, China. If a patient is clinically or epidemiologically suspected of COVID-19, appropriate infection and prevention control measures such as standard, contact, and droplet precaution are needed until the patient is proven to be true-negative.

2021-10-13 09:26:54
3 + 1 Twitter

3 0 0 0 OA Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan

著者: Mugen Ujiie Shinya Tsuzuki Michiyo Suzuki Masayuki Ota Tetsuya Suzuki Hidetoshi Nomoto Kei Yamamoto Sho Saito Akatsuki Kokaze Noriko Kinoshita
出版者: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
雑誌: Japanese Journal of Infectious Diseases (ISSN:13446304)
巻号頁・発行日: vol.74, no.5, pp.399-404, 2021-09-30 (Released:2021-09-22)
参考文献数: 18
被引用文献数: 6

Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is generally used for booster vaccination of infants in Europe and the United States to avoid increased reactogenicity after diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination. However, Japan has extended the use of additional DTaP vaccination without reducing the antigen dose for diphtheria and pertussis in adolescents and adults, despite limited reports on its safety in adults. This prospective, observational, questionnaire-based study investigated the occurrence of adverse events (AEs) following DTaP vaccination between June 2018 and June 2019 in participants aged 10 years or older. Of the 250 eligible participants, 235 (94%) responded regarding AEs. Among them, 133 (56.6%) reported AEs, of which 39 reported systemic AEs (16.6%) and 120 reported local AEs (51.1%) attributed to DTaP vaccination. The incidence of local AEs was markedly higher with DTaP vaccination than with non-DTaP vaccination (51.1% vs. 10.5%), and AEs appeared later (P < 0.01) and lasted longer (P < 0.01) with DTaP vaccination. However, more than 75% of these AEs resolved within 7 days. DTaP vaccination was not associated with any serious AEs. These results indicate that the DTaP vaccine can be widely used as a booster in adults as an alternative to the Tdap vaccine.

2021-09-23 06:25:14
3 + 13 Twitter

3 0 0 0 OA Safety of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine in adults in Japan

著者: Mugen Ujiie Shinya Tsuzuki Michiyo Suzuki Masayuki Ota Tetsuya Suzuki Hidetoshi Nomoto Kei Yamamoto Sho Saito Akatsuki Kokaze Noriko Kinoshita
出版者: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
雑誌: Japanese Journal of Infectious Diseases (ISSN:13446304)
巻号頁・発行日: pp.JJID.2020.947, (Released:2021-01-29)
参考文献数: 18
被引用文献数: 6

Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine is generally used for booster vaccination in Europe and the United States to avoid increased reactogenicity after diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination in infants. However, Japan has extended the use of additional DTaP vaccination without reducing the antigen dose for diphtheria and pertussis to adolescents and adults despite limited reports on its safety in adults. This prospective observational questionnaire-based study investigated the occurrence of adverse events (AEs) following DTaP vaccination between June 2018 and June 2019 in participants aged 10 years or older. Of 250 eligible participants, 235 (94%) responded regarding AEs. Of these 235 participants, 133 (56.6%) reported AEs, with 39 reporting systemic AEs (16.6%) and 120 reporting local AEs (51.1%) attributed to DTaP vaccination. The incidence of local AEs was much higher with DTaP than with non-DTaP vaccinations (51.1% vs. 10.2%), and the AEs appeared later (p<0.01) and lasted longer (p<0.01) with DTaP vaccination. However, more than 75% of these AEs resolved within 7 days. DTaP vaccination was not associated with any serious AEs. These results indicate that the DTaP vaccine can be widely used as a booster in adults as an alternative to the Tdap vaccine.

2021-03-10 08:44:58
3 + 11 Twitter

3 0 0 0 OA Non-COVID-19 Patients with Life-threatening Diseases Who Visited a Fever Clinic: A Single-Center, Observational Study in Tokyo, Japan

著者: Yutaro Akiyama Shinichiro Morioka Yuji Wakimoto Akira Kawashima Kohei Kanda Ayako Okuhama Tetsuya Suzuki Yusuke Miyazato Hidetoshi Nomoto Satoshi Ide Takato Nakamoto Keiji Nakamura Masayuki Ota Yuki Moriyama Saho Takaya Kota Yamada Maho Taguchi Erika Sugito Shinji Izuka Kenji Ishiguro Toshiaki Kobayashi Wataru Miyake Shuji Kubota Masahiro Ishikane Noriko Kinoshita Kei Yamamoto Mugen Ujiie Satoshi Kutsuna Kayoko Hayakawa Sho Saito Norio Ohmagari
出版者: The Japanese Society of Internal Medicine
雑誌: Internal Medicine (ISSN:09182918)
巻号頁・発行日: pp.5614-20, (Released:2020-11-02)
参考文献数: 7
被引用文献数: 2

Objective In fever clinics screening coronavirus disease (COVID-19), there could be patients with life-threatening diseases that physicians should not overlook. We exploratorily investigated the final diagnosis among non-COVID-19 hospitalized patients who visited the fever clinic. Methods This was a retrospective, observational, and single-centered study conducted in the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. We conducted a retrospective chart review of patients who visited the fever clinic in the NCGM from 11 March 2020 to 24 April 2020. Patients Patients who met the following clinical criteria visited the fever clinic in the NCGM: (1) body temperature >37.5°C, (2) any symptoms consistent with COVID-19 or (3) referral from local healthcare facilities. In the fever clinic, all patients who met the above criteria had severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test with nasopharyngeal swab specimens. Patients with severe symptoms or an unstable condition were sent to an outpatient clinic for infectious diseases for further evaluation and treatment. Results Among 1,470 patients who visited the fever clinic, 84 patients were hospitalized, and 45 of them were diagnosed as having COVID-19. Among the remaining 39 non-COVID-19 patients, there were nine patients with life-threatening diseases. The life-threatening diseases included acute heart failure, septic shock, pneumocystis pneumonia, peritonsillar abscess, and necrotizing fasciitis. Conclusion Physicians should evaluate each patient carefully while considering other life-threatening conditions even in such a COVID-19 pandemic era.

2020-11-06 07:02:23
3 + 6 Twitter

3 0 0 0 OA 摂取可能食品の調査による咀嚼能力の評価

著者: 内田達郎鈴木哲也織田展輔ウチダタツロウスズキテツヤオダノブスケ Tatsuro UCHIDA Tetsuya SUZUKI Nobusuke ODA
雑誌: 岩手医科大学歯学雑誌 = Dental journal of Iwate Medical University
巻号頁・発行日: vol.32, no.2, pp.105-111, 2007-08-16

2017-11-20 12:17:05
3 + 0 Twitter

http://id.nii.ac.jp/1181/00001468/

2 0 0 0 OA SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine

著者: Kayoko Hayakawa Satoshi Kutsuna Takeo Kawamata Yuko Sugiki Chiharu Nonaka Keiko Tanaka Michi Shoji Masaki Nagai Shunsuke Tezuka Kazuyuki Shinya Hiroki Saito Takahiro Harada Nin Moriya Motoyuki Tsuboi Masataro Norizuki Yasuo Sugiura Yasuyo Osanai Masaya Sugiyama Ayako Okuhama Kohei Kanda Yuji Wakimoto Mugen Ujiie Shinichiro Morioka Kei Yamamoto Noriko Kinoshita Masahiro Ishikane Sho Saito Yuki Moriyama Masayuki Ota Keiji Nakamura Takato Nakamoto Satoshi Ide Hidetoshi Nomoto Yutaro Akiyama Tetsuya Suzuki Yusuke Miyazato Yoshiaki Gu Nobuaki Matsunaga Shinya Tsuzuki Yumiko Fujitomo Yoshiki Kusama Hiroyuki Shichino Masao Kaneshige Junko Yamanaka Miki Saito Masayuki Hojo Masao Hashimoto Shinyu Izumi Jin Takasaki Manabu Suzuki Keita Sakamoto Yukio Hiroi Sakurako Emoto Makoto Tokuhara Toshiaki Kobayashi Koichiro Tomiyama Fumihiko Nakamura Norio Ohmagari Haruhito Sugiyama
出版者: National Center for Global Health and Medicine
雑誌: Global Health & Medicine (ISSN:24349186)
巻号頁・発行日: pp.2020.01036, (Released:2020-04-29)
参考文献数: 11
被引用文献数: 25

2020-05-04 10:57:25
2 + 3 Twitter

1 0 0 0 OA A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan

著者: Rubuna Sato Masahiro Ishikane Noriko Kinoshita Tetsuya Suzuki Takato Nakamoto Kayoko Hayakawa Norifumi Bekki Hisao Hara Norio Ohmagari
出版者: National Center for Global Health and Medicine
雑誌: Global Health & Medicine (ISSN:24349186)
巻号頁・発行日: vol.2, no.3, pp.190-192, 2020-06-30 (Released:2020-07-04)
参考文献数: 13
被引用文献数: 1 14

2021-05-31 02:40:12
1 + 0 Twitter

1 0 0 0 OA Durable Transgene Expression Driven by CpG-Free and -Containing Promoters in Plasmid DNA with CpG-Free Backbone

著者: Tetsuya Suzuki Takuya Goda Hiroyuki Kamiya
出版者: The Pharmaceutical Society of Japan
雑誌: Biological and Pharmaceutical Bulletin (ISSN:09186158)
巻号頁・発行日: vol.41, no.9, pp.1489-1493, 2018-09-01 (Released:2018-09-01)
参考文献数: 32
被引用文献数: 2 4

The duration of transgene expression from plasmid DNAs is important for gene therapy with nonviral vectors. In the present study, various cytosine-phosphate-guanine (CpG)-free and CpG-containing transcription regulatory sequences were introduced into plasmid DNAs with a CpG-free backbone. The transgenes encoding mouse secreted alkaline phosphatase and Gaussia princeps luciferase, which are both apparently non-immunogenic, were used as reporters. The plasmid DNAs were injected by the hydrodynamics-based method, and the expression was monitored for 28 d. All transcription regulatory sequences achieved long-term expression, with different expression levels depending on the sequences themselves. These results suggested that durable transgene expression at the proper level can be achieved with plasmid DNAs containing the CpG-free backbone.

2020-11-24 23:00:28
1 + 0 Twitter